Acurex Biosciences

𝗔𝗰𝘂𝗿𝗲𝘅'𝘀 𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗶𝘀 𝘁𝗼 𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝘁𝗵𝗮𝘁 𝗳𝘂𝗻𝗱𝗮𝗺𝗲𝗻𝘁𝗮𝗹𝗹𝘆 𝗺𝗼𝗱𝗶𝗳𝘆 𝘁𝗵𝗲 𝗰𝗼𝘂𝗿𝘀𝗲 𝗼𝗳 𝗻𝗲𝘂𝗿𝗼𝗱𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀, 𝗮𝗶𝗺𝗶𝗻𝗴 𝗻𝗼𝘁 𝗷𝘂𝘀𝘁 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁 𝘁𝗵𝗲 𝘀𝘆𝗺𝗽𝘁𝗼𝗺𝘀 𝗯𝘂𝘁 𝘁𝗼 𝘀𝗹𝗼𝘄 𝗼𝗿 𝘀𝘁𝗼𝗽 𝘁𝗵𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲’𝘀 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀𝗶𝗼𝗻. Acurex’s platform and founding intellectual property are based on a Stanford University breakthrough discovery enabling the identification of druggable targets that induce biomarker changes in Parkinson's disease. Acurex’s platform has generated two oral small-molecule therapeutic programs that cross the blood-brain barrier and protect neurons derived from Parkinson’s disease patients. Acurex’s lead program has begun IND-enabling studies, and the second program to a distinct target is in lead development. Acurex is supported by funding from Stanford University, the University of California, the Michael J. Fox Foundation for Parkinson’s Research, Parkinson’s UK, The Silverstein Foundation for Parkinson’s with GBA, and the National Institute on Aging.